Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

3 terminated/withdrawn out of 15 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

7(53.8%)

Phase 3

4(30.8%)

Phase 1

1(7.7%)

Phase 4

1(7.7%)

13Total

Phase 2(7)

Phase 3(4)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT03969953Phase 3Completed

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Role: collaborator

NCT04389827Completed

Global Kidney Patient Trials Network

Role: collaborator

NCT07098663Phase 2Recruiting

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Role: collaborator

NCT07027670Phase 2Completed

Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery

Role: collaborator

NCT04620590Phase 4Completed

Dapagliflozin Treatment in Type 2 Diabetes

Role: lead

NCT04974008Phase 2Active Not Recruiting

Osteosarcoma Maintenance Therapy With OST31-164

Role: lead

NCT04492722Phase 2Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Role: collaborator

NCT05200013Phase 1Completed

BAT7104 in Patients With Advanced Solid Tumours

Role: collaborator

NCT01330966Phase 2Completed

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Role: lead

NCT04350593Phase 3Completed

Dapagliflozin in Respiratory Failure in Patients With COVID-19

Role: collaborator

NCT04808531Phase 3Unknown

NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers

Role: collaborator

NCT03821038Phase 2Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

Role: collaborator

NCT01759303Phase 2Terminated

Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung

Role: lead

NCT03403712Phase 3Completed

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Role: collaborator

NCT03078244Completed

Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension

Role: lead

All 15 trials loaded